{"id":470611,"date":"2021-04-05T07:33:27","date_gmt":"2021-04-05T11:33:27","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=470611"},"modified":"2021-04-05T07:33:27","modified_gmt":"2021-04-05T11:33:27","slug":"otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\/","title":{"rendered":"Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, April  05, 2021  (GLOBE NEWSWIRE) &#8212; Otonomy, Inc.\u00a0(Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of previously disclosed clinical results from the successful OTO-313 Phase 1\/2 trial at the upcoming American Neurotology Society\u2019s 56<sup>th<\/sup> Annual Spring Meeting, which is part of the Combined Otolaryngology Spring Meeting (COSM), to be held virtually April 7-11, 2021. The oral presentation will be delivered on April 10, 2021 at 5:07 p.m. EDT by Kenneth Maxwell, M.D., a Neurotologist at Piedmont Ear Nose &amp; Throat Associates in Winston-Salem, North Carolina. Dr. Maxwell was an investigator in the trial.<\/p>\n<p>\u201cWe are pleased to have the opportunity to present clinical results from the OTO-313 Phase 1\/2 trial to the neurotology community during the COSM conference,\u201d said David A. Weber, Ph.D., president and CEO of Otonomy. \u201cTinnitus is a common condition seen by neurotologists who unfortunately have no approved drug treatments to offer patients. The Phase 2 trial we recently initiated builds on the encouraging Phase 1\/2 results and is a significant step forward for this important program.\u201d<\/p>\n<p>\n        <strong>About Otonomy<\/strong><\/p>\n<p>Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs with a focus on hearing loss and tinnitus. For additional information please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KJj0ON1RNpj1ePcI_SLXqzy_KOl5uDhcAHaIjJ4xErUfsPtCeg_avJASBCBa1IqrF-Vq5PIHLNgxaDPKUug_4A==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.otonomy.com<\/a>.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>Media Inquiries:<br \/>Spectrum Science<br \/>Chlo\u00e9-Anne Ramsey<br \/>Vice President<br \/>404.865.3601<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Vj0DEH58wefSxa-B8gcGdQ6MlcaEoWJhy3H2pyCeNxavwHSfmWnj2FL9J3cERoSgRNYGSJ5n6q-N9zTR1PWM9Sx09pDRNTwmzggkyGDW96ceH0N9a6CaaVDUnpzj20-J\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">cramsey@spectrumscience.com<\/a><\/p>\n<p>Investor Inquiries:<br \/>Westwicke ICR<br \/>Robert H. Uhl<br \/>Managing Director<br \/>858.356.5932<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ucCHSrPqKh9JQntnaVtV_PrZLRxXRA4pg36p78U2KG5Edzb3cI8xeJNIg4iKBkI1qj4gHioPbS_58mjS3_OouvnjcLhJ5qhV3Z8dsZtWjLE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">robert.uhl@westwicke.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTExMSM0MTA0MjYyIzIwMTEwNTU=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/35c499da-861f-482c-8c4f-78538845587e\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) &#8212; Otonomy, Inc.\u00a0(Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of previously disclosed clinical results from the successful OTO-313 Phase 1\/2 trial at the upcoming American Neurotology Society\u2019s 56th Annual Spring Meeting, which is part of the Combined Otolaryngology Spring Meeting (COSM), to be held virtually April 7-11, 2021. The oral presentation will be delivered on April 10, 2021 at 5:07 p.m. EDT by Kenneth Maxwell, M.D., a Neurotologist at Piedmont Ear Nose &amp; Throat Associates in Winston-Salem, North Carolina. Dr. Maxwell was an investigator in the trial. \u201cWe are pleased to have the opportunity to present clinical results from the OTO-313 Phase &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-470611","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) &#8212; Otonomy, Inc.\u00a0(Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of previously disclosed clinical results from the successful OTO-313 Phase 1\/2 trial at the upcoming American Neurotology Society\u2019s 56th Annual Spring Meeting, which is part of the Combined Otolaryngology Spring Meeting (COSM), to be held virtually April 7-11, 2021. The oral presentation will be delivered on April 10, 2021 at 5:07 p.m. EDT by Kenneth Maxwell, M.D., a Neurotologist at Piedmont Ear Nose &amp; Throat Associates in Winston-Salem, North Carolina. Dr. Maxwell was an investigator in the trial. \u201cWe are pleased to have the opportunity to present clinical results from the OTO-313 Phase &hellip; Continue reading &quot;Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-05T11:33:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTExMSM0MTA0MjYyIzIwMTEwNTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting\",\"datePublished\":\"2021-04-05T11:33:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\\\/\"},\"wordCount\":295,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMTExMSM0MTA0MjYyIzIwMTEwNTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\\\/\",\"name\":\"Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMTExMSM0MTA0MjYyIzIwMTEwNTU=\",\"datePublished\":\"2021-04-05T11:33:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMTExMSM0MTA0MjYyIzIwMTEwNTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMTExMSM0MTA0MjYyIzIwMTEwNTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting - Market Newsdesk","og_description":"SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) &#8212; Otonomy, Inc.\u00a0(Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of previously disclosed clinical results from the successful OTO-313 Phase 1\/2 trial at the upcoming American Neurotology Society\u2019s 56th Annual Spring Meeting, which is part of the Combined Otolaryngology Spring Meeting (COSM), to be held virtually April 7-11, 2021. The oral presentation will be delivered on April 10, 2021 at 5:07 p.m. EDT by Kenneth Maxwell, M.D., a Neurotologist at Piedmont Ear Nose &amp; Throat Associates in Winston-Salem, North Carolina. Dr. Maxwell was an investigator in the trial. \u201cWe are pleased to have the opportunity to present clinical results from the OTO-313 Phase &hellip; Continue reading \"Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-05T11:33:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTExMSM0MTA0MjYyIzIwMTEwNTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting","datePublished":"2021-04-05T11:33:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\/"},"wordCount":295,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTExMSM0MTA0MjYyIzIwMTEwNTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\/","name":"Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTExMSM0MTA0MjYyIzIwMTEwNTU=","datePublished":"2021-04-05T11:33:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTExMSM0MTA0MjYyIzIwMTEwNTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTExMSM0MTA0MjYyIzIwMTEwNTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/otonomy-announces-presentation-of-oto-313-clinical-results-at-american-neurotology-society-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/470611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=470611"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/470611\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=470611"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=470611"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=470611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}